Evidence map›Paper›PMID 37962093›Full record

ArticleCancer2024

Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial.

Jingran Ji, Marie Bae, Can-Lan Sun, Tanya M Wildes, Rachel A Freedman, Allison Magnuson, Tracey O'Connor, Beverly Moy, Heidi D Klepin, Andrew E Chapman and 9 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 1 country.

Jingran JiDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA.ORCID 0000-0002-7284-0709
Marie BaeDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA.
Can-Lan SunDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA.
Tanya M WildesDivision of Hematology/Oncology, University of Nebraska Medical Center/Nebraska Medicine, Omaha, Nebraska, USA.
Rachel A FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Allison MagnusonDepartment of Medicine, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0002-0968-8265
Tracey O'ConnorDepartment of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Beverly MoyDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Heidi D KlepinDepartment of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Andrew E ChapmanDepartment of Medical Oncology, Sidney Kimmel Cancer Center/Jefferson Health, Philadelphia, Pennsylvania, USA.
William P TewDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-5115-4470
Efrat DotanDepartment of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-5762-512X
Mary Anne FentonDepartment of Medicine, Brown University, Providence, Rhode Island, USA.
Heeyoung KimDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA.
Vani KatheriaDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA.
Cary P GrossDepartment of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-4974-935X
Harvey J CohenDepartment of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Hyman B MussDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-2862-9970
Mina S SedrakDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA.ORCID 0000-0002-8379-391X
City of Hope · USBrown University · USDana-Farber Cancer Institute · USDuke University · USFox Chase Cancer Center · USMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USNebraska Medical Center · USThomas Jefferson University Hospital · USUniversity of California, Los Angeles · USUniversity of North Carolina at Chapel Hill · USUniversity of Rochester Medical Center · USWake Forest University · USYale University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
Washington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7M
Geriatric Oncology Research Infrastructure to Improve Clinical CareR33AG059206 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WILLIAM DALE, Heidi Diana Klepin · 2020 to 2026
$5.1M
Targeting Senescence to Mitigate Chemotherapy-induced Functional DeclineR01CA280088 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Mina S Sedrak · 2023 to 2026
$2.7M
Clinical and Biological Predictors of Chemotherapy Toxicity in Older AdultsR01AG037037 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI HURRIA, ARTI · 2011 to 2015
$2.4M
Mentoring the Next Generation of Geriatric Oncology Researchers in Patient-Oriented Research to Improve the Care of Older Adults with CancerK24AG055693 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WILLIAM DALE · 2018 to 2026
$1.4M
Mitigating Cancer-Related Cognitive Dysfunction in Older Adults with Breast CancerK76AG064394 · NIA · UNIVERSITY OF ROCHESTER · PI MAGNUSON, ALLISON MARIAN · 2019 to 2023
$1.3M
Targeting Senescence to Improve Frailty in Older Cancer SurvivorsK76AG074918 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEDRAK, MINA S · 2022 to 2024
$729k
Minimizing Physical Function Decline in Older Adults Receiving ChemotherapyK23AG038361 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KLEPIN, HEIDI DIANA · 2011 to 2014
$562k
Using Senolytics to Improve Physical Function in Older Breast Cancer SurvivorsR21CA277660 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEDRAK, MINA S · 2023 to 2024
$422k
NCI NIH HHS K12 CA001727NCI NIH HHS K12 CA167540NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA280088NCI NIH HHS R21 CA277660NCI NIH HHS UG1 CA189961NIA NIH HHS K23 AG038361NIA NIH HHS K24 AG055693NIA NIH HHS K76 AG064394NIA NIH HHS K76 AG074918NIA NIH HHS R01 AG037037NIA NIH HHS R03 AG064377NIA NIH HHS R33 AG059206NIH HHS K12 CA001727NIH HHS K12 CA167540NIH HHS K23 AG038361NIH HHS K76 AG064394NIH HHS K76 AG074918NIH HHS P30 CA008748NIH HHS R01 AG037037NIH HHS R01 CA280088NIH HHS R03 AG064377NIH HHS R21 CA277660Susan G. Komen CCR14298143
6 · The paper itself

Abstract

backgroundOlder women with breast cancer frequently experience toxicity-related hospitalizations during adjuvant chemotherapy. Although the geriatric assessment can identify those at risk, its use in clinic remains limited. One simple, low-cost marker of vulnerability in older persons is fall history. Here, the authors examined whether falls prechemotherapy can identify older women at risk for toxicity-related hospitalization during adjuvant chemotherapy for breast cancer.

methodsIn a prospective study of women >65 years old with stage I-III breast cancer treated with adjuvant chemotherapy, the authors assessed baseline falls in the past 6 months as a categorical variable: no fall, one fall, and more than one fall. The primary end point was incident hospitalization during chemotherapy attributable to toxicity. Multivariable logistic regression was used to examine the association between falls and toxicity-related hospitalization, adjusting for sociodemographic, disease, and geriatric covariates.

resultsOf the 497 participants, 60 (12.1%) reported falling before chemotherapy, and 114 (22.9%) had one or more toxicity-related hospitalizations. After adjusting for sociodemographic, disease, and geriatric characteristics, women who fell more than once within 6 months before chemotherapy had greater odds of being hospitalized from toxicity during chemotherapy compared to women who did not fall (50.0% vs. 20.8% experienced toxicity-related hospitalization, odds ratio, 4.38; 95% confidence interval, 1.66-11.54, p = .003).

conclusionsIn this cohort of older women with early breast cancer, women who experienced more than one fall before chemotherapy had an over 4-fold increased risk of toxicity-related hospitalization during chemotherapy, independent of sociodemographic, disease, and geriatric factors.

Indexed as

Breast NeoplasmsAgedAged, 80 and overChemotherapy, AdjuvantFemaleGeriatric AssessmentHospitalizationHumansProspective Studiesadjuvant chemotherapybreast cancerfallsgeriatric assessmenthospitalizationolder adultstoxicity

Identifiers

PMID37962093
PMCPMC10922500
OpenAlexW4388656891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.